The compounds of Formula I wherein R 1 is C alkylOC alkyl, cyclohexyl, or tetrahydropyranyl, wherein said cyclohexyl or tetrahydropyranyl may be optionally substituted with one substituent selected from the group consisting of: OC alkyl, OH, CH 2 CH 3, -CN, NH 2, NH(CH 3), N(CH 3) 2, or OCF 3; R 2 is H, C NHCH 2 CH(CH 3) 2, or C NHCH 3; R 3 is -SO 2 -R c, H, -CN, C alkyl, C alkylNA 1 A 2, C alkylC NA 1 A 2, C cycloalkyl, oxetan-3-yl, -(CH 2) n Ph-R aa, -C alkylCO 2 C alkyl, 4,5 dihydro thiazolyl, 4,5 dihydro oxazolyl, thiazolyl, oxazolyl, pyrimidinyl, pyridyl, pyrazyl, furyl, or 3-methyl 1,2,4 oxadiazol-5-yl; wherein said 4,5 dihydro thiazolyl, 4,5 dihydro oxazolyl, thiazolyl, oxazolyl, pyrimidinyl, pyridyl, pyrazyl, and furyl may be optionally substituted with up to two substituent independently selected from R aa. n is 0, 1, 2, or 3; R a is H, NA 1 A 2, NHCH 2 CH 2 NA 1 A 2, C alkylNA 1 A 2, OC alkylNA 1 A 2, C alkyl, OC alkyl, -CN, -CH 2 CH 2 Ph, -CH 2 OPh, -CH 2 OC C alkyl, -CH 2 OC alkyl, -CH 2 NHBoc,-OCH 2 CH=CH 2, -OCH 2 CH 2 CF 3, -OCH 2 CH 2 C(CH 3) 2 OH, -OCH 2 CH 2 OC alkyl, -OCH 2 CH 2 CN, -OPh-R aa, -OC alkyl-Ph-R aa, phenyl-R aa, oxazol-2-yl, oxazol-4-yl, isoxazol-5-yl, or thiazol-2-yl; R aa is H, OC alkyl, OCF 3, -CO 2 H, Cl, Br, F, or -CN; R b is NA 1 A 2; R c is NA 1 A 2, CH 2 Ph, CH 2 CH 2 Ph, or C alkyl; A 1 is H, C alkyl, Ph-R aa, C CH 3, CH 2 Ph-R aa, or C alkylOC alkyl; A 2 is H, C alkyl; or A 1 and A 2 may be taken together with the nitrogen to which they are attached to form a ring selected from the group consisting of: R 4 is CH 2 Ph, wherein said Ph is optionally substituted with up to two groups selected from CF 3, OCF 3, and F; R 5 is H; or R 4 and R 5 are taken together with their attached nitrogen to form a pair of fused rings selected from the group consisting of: R 6 is CF 3, or OCF 3; Z 1 is CH 2 or C=O; Z 2 is CH 2 or Z 2 may be C=O provided that Z 1 and Z 2 are not both simultaneously C=O; and pharmaceutically acceptable salts thereof. R 1 is C alkylOC alkyl, cyclohexyl, or tetrahydropyranyl, wherein said cyclohexyl or tetrahydropyranyl may be optionally substituted with one substituent selected from the group consisting of: OC alkyl, OH, CH 2 CH 3, -CN, NH 2, NH(CH 3), N(CH 3) 2, or OCF 3; R 2 is H, C NHCH 2 CH(CH 3) 2, or C NHCH 3; R 3 is -SO 2 -R c, H, -CN, C alkyl, C alkylNA 1 A 2, C alkylC NA 1 A 2, C cycloalkyl, oxetan-3-yl, -(CH 2) n Ph-R aa, -C alkylCO 2 C alkyl, 4,5 dihydro thiazolyl, 4,5 dihydro oxazolyl, thiazolyl, oxazolyl, pyrimidinyl, pyridyl, pyrazyl, furyl, or 3-methyl 1,2,4 oxadiazol-5-yl; wherein said 4,5 dihydro thiazolyl, 4,5 dihydro oxazolyl, thiazolyl, oxazolyl, pyrimidinyl, pyridyl, pyrazyl, and furyl may be optionally substituted with up to two substituent independently selected from R aa. n is 0, 1, 2, or 3; R a is H, NA 1 A 2, NHCH 2 CH 2 NA 1 A 2, C alkylNA 1 A 2, OC alkylNA 1 A 2, C alkyl, OC alkyl, -CN, -CH 2 CH 2 Ph, -CH 2 OPh, -CH 2 OC C alkyl, -CH 2 OC alkyl, -CH 2 NHBoc,-OCH 2 CH=CH 2, -OCH 2 CH 2 CF 3, -OCH 2 CH 2 C(CH 3) 2 OH, -OCH 2 CH 2 OC alkyl, -OCH 2 CH 2 CN, -OPh-R aa, -OC alkyl-Ph-R aa, phenyl-R aa, oxazol-2-yl, oxazol-4-yl, isoxazol-5-yl, or thiazol-2-yl; R aa is H, OC alkyl, OCF 3, -CO 2 H, Cl, Br, F, or -CN; R b is NA 1 A 2; R c is NA 1 A 2, CH 2 Ph, CH 2 CH 2 Ph, or C alkyl; A 1 is H, C alkyl, Ph-R aa, C CH 3, CH 2 Ph-R aa, or C alkylOC alkyl; A 2 is H, C alkyl; or A 1 and A 2 may be taken together with the nitrogen to which they are attached to form a ring selected from the group consisting of: R 4 is CH 2 Ph, wherein said Ph is optionally substituted with up to two groups selected from CF 3, OCF 3, and F; R 5 is H; or R 4 and R 5 are taken together with their attached nitrogen to form a pair of fused rings selected from the group consisting of: R 6 is CF 3, or OCF 3; Z 1 is CH 2 or C=O; Z 2 is CH 2 or Z 2 may be C=O provided that Z 1 and Z 2 are not both simultaneously C=O;